1950
Established in Israel to manufacture finished pharmaceutical products
1961
Started chemical synthesis (API production) in Israel
1984
Established topical product operations in Canada
1988
Taro enters the U.S. market with its first FDA-approved topical product.
2003
Established TaroPharma branded division in U.S.
2010
Sun Pharma acquires a controlling interest In Taro
2012
Over $1 Billion Gross Sales (IMS Calendar Year Sales 2012)
2012
Taro re-listed on the NYSE providing improved access to capital markets.
2022
Taro Completes Acquisition of Alchemee.
2024
On June 24, 2024, Taro became a private company and a wholly-owned subsidiary of Sun Pharma and its shares ceased to trade on the NYSE.